Absorption and disposition of the sphingosine 1-phosphate receptor modulator fingolimod (FTY720) in healthy volunteers: A case of xenobiotic biotransformation following endogenous metabolic pathways

Drug Metabolism and Disposition

Volumn 39, Issue 2, 2011, Pages 199-207

  Zollinger, Markus ^a   Gschwind, Hans Peter ^a   Jin, Yi ^a   Sayer, Claudia ^a   Zécri, Frédéric ^a   Hartmann, Stefan ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ATROPINE; CARBON 14; CARBOXYLIC ACID; CERAMIDE DERIVATIVE; CYTOCHROME P450; CYTOCHROME P450 4F; FINGOLIMOD; FINGOLIMOD PHOSPHATE; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; DEPHOSPHORYLATION; DRUG ABSORPTION; DRUG CONJUGATION; DRUG DETERMINATION; DRUG DISPOSITION; DRUG ELIMINATION; DRUG HYDROXYLATION; DRUG METABOLISM; DRUG OXIDATION; DRUG STRUCTURE; DRUG TRANSFORMATION; ENANTIOMER; FATTY ACID OXIDATION; FECES; HUMAN; HUMAN EXPERIMENT; HYPOTENSION; ISOTOPE LABELING; MALE; MASS SPECTROMETRY; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; PHOSPHORYLATION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RADIOACTIVITY; SINGLE DRUG DOSE; SINUS BRADYCARDIA; SYNCOPE; TIME TO MAXIMUM PLASMA CONCENTRATION; URINE;

ABSORPTION; ADMINISTRATION, ORAL; ADULT; BIOTRANSFORMATION; CARBON RADIOISOTOPES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FECES; HUMANS; MALE; MIDDLE AGED; MOLECULAR STRUCTURE; OXIDATION-REDUCTION; PROPYLENE GLYCOLS; RECEPTORS, LYSOSPHINGOLIPID; SPHINGOSINE; TANDEM MASS SPECTROMETRY; TIME FACTORS; TISSUE DISTRIBUTION; XENOBIOTICS;

EID: 79251529897     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.110.035907     Document Type: Article

References (26)

1. Albert R, Hinterding K, Brinkmann V, Guerini D, Müller-Hartwieg C, Knecht H, Simeon C, Streiff M, Wagner T, Welzenbach K, et al. (2005) Novel immunomodulator FTY720 is phosphorylated in rats and humans to form a single stereoisomer. Identification, chemical proof, and biological characterization of the biologically active species and its enantiomer. J Med Chem 48:5373-5377.
2. Billich A, Bornancin F, Dévay P, Mechtcheriakova D, Urtz N, and Baumruker T (2003) Phosphorylation of the immunomodulatory drug FTY720 by sphingosine kinases. J Biol Chem 278:47408-47415.
3. Brinkmann V (2007) Sphingosine 1-phosphate receptors in health and disease: mechanistic insights from gene deletion studies and reverse pharmacology. Pharmacol Ther 115:84-105.
4. Brinkmann V, Davis MD, Heise CE, Albert R, Cottens S, Hof R, Bruns C, Prieschl E, Baumruker T, Hiestand P, et al. (2002) The immune modulator FTY720 targets sphingosine 1-phosphate receptors. J Biol Chem 277:21453-21457.
5. Brown BA, Kantesaria PP, and McDevitt LM (2007) Fingolimod: a novel immunosuppressant for multiple sclerosis. Ann Pharmacother 41:1660-1668.
6. Bryan L, Kordula T, Spiegel S, and Milstien S (2008) Regulation and functions of sphingosine kinases in the brain. Biochim Biophys Acta 1781:459-466.
7. Budde K, Schmouder RL, Brunkhorst R, Nashan B, Lücker PW, Mayer T, Choudhury S, Skerjanec A, Kraus G, and Neumayer HH (2002) First human trial of FTY720, a novel immunomodulator, in stable renal transplant patients. J Am Soc Nephrol 13:1073-1083.
8. Chiba K (2005) FTY720, a new class of immunomodulator, inhibits lymphocyte egress from secondary lymphoid tissues and thymus by agonistic activity at sphingosine 1-phosphate receptors. Pharmacol Ther 108:308-319.
9. Foster CA, Howard LM, Schweitzer A, Persohn E, Hiestand PC, Balatoni B, Reuschel R, Beerli C, Schwartz M, and Billich A (2007) Brain penetration of the oral immunomodulatory drug FTY720 and its phosphorylation in the central nervous system during experimental autoimmune encephalomyelitis: consequences for mode of action in multiple sclerosis. J Pharmacol Exp Ther 323:469-475.
10. Hale JJ, Yan L, Neway WE, Hajdu R, Bergstrom JD, Milligan JA, Shei GJ, Chrebet GL, Thornton RA, Card D, et al. (2004) Synthesis, stereochemical determination and biochemical characterization of the enantiomeric phosphate esters of the novel immunosuppressive agent FTY720. Bioorg Med Chem 12:4803-4807.
11. Jin Y, Zollinger M, Borell H, Zimmerlin A, and Patten CJ (2011) CYP4F enzymes are responsible for the elimination of fingolimod (FTY720), a novel treatment of relapsing multiple sclerosis. Drug Metab Dispos 39:191-198.
12. Kappos L, Antel J, Comi G, Montalban X, O'Connor P, Polman CH, Haas T, Korn AA, Karlsson G, Radue EW, et al. (2006) Oral fingolimod (FTY720) for relapsing multiple sclerosis. N Engl J Med 355:1124-1140. (Pubitemid 44394919)
13. Kiuchi M, Adachi K, Tomatsu A, Chino M, Takeda S, Tanaka Y, Maeda Y, Sato N, Mitsutomi N, Sugahara K, et al. (2005) Asymmetric synthesis and biological evaluation of the enantiomeric isomers of the immunosuppressive FTY720-phosphate. Bioorg Med Chem 13:425-432.
14. Kovarik JM, Hartmann S, Bartlett M, Riviere GJ, Neddermann D, Wang Y, Port A, and Schmouder RL (2007a) Oral-intravenous crossover study of fingolimod pharmacokinetics, lymphocyte responses and cardiac effects. Biopharm Drug Dispos 28:97-104.
15. Kovarik JM, Schmouder R, Barilla D, Wang Y, and Kraus G (2004) Single-dose FTY720 pharmacokinetics, food effect, and pharmacological responses in healthy subjects. Br J Clin Pharmacol 57:586-591.
16. Kovarik JM, Schmouder RL, Hartmann S, Riviere GJ, Picard F, Voss B, Weiss M, Wagner F, and Schmidt HH (2006) Fingolimod (FTY720) in severe hepatic impairment: pharmacokinetics and relationship to markers of liver function. J Clin Pharmacol 46:149-156.
17. Kovarik JM, Schmouder RL, Serra D, Wang Y, Wiegand H, Dilzer SC, and Lasseter KC (2005) FTY720 pharmacokinetics in mild to moderate hepatic impairment. J Clin Pharmacol 45:446-452.
18. Kovarik JM, Slade A, Voss B, Schmidli H, Riviere GJ, Picard F, Sugita Y, Kawai R, Mee-Lee D, and Schmouder RL (2007b) Ethnic sensitivity study of fingolimod in white and Asian subjects. Int J Clin Pharmacol Ther 45:98-109.
19. Mandala S, Hajdu R, Bergstrom J, Quackenbush E, Xie J, Milligan J, Thornton R, Shei GJ, Card D, Keohane C, et al. (2002) Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists. Science 296:346-349.
20. Mechtcheriakova D, Wlachos A, Sobanov J, Bornancin F, Zlabinger G, Baumruker T, and Billich A (2007) FTY720-phosphate is dephosphorylated by lipid phosphate phosphatase 3. FEBS Lett 581:3063-3068.
21. Merrill AH Jr (2002) De novo sphingolipid biosynthesis: a necessary, but dangerous, pathway. J Biol Chem 277:25843-25846.
22. Ortiz de Montellano PR (2008) Mechanism and role of covalent heme binding in the CYP4 family of P450 enzymes and the mammalian peroxidases. Drug Metab Rev 40:405-426.
23. Paugh SW, Payne SG, Barbour SE, Milstien S, and Spiegel S (2003) The immunosuppressant FTY720 is phosphorylated by sphingosine kinase type 2. FEBS Lett 554:189-193. (Pubitemid 37324838)
24. Pinschewer DD, Ochsenbein AF, Odermatt B, Brinkmann V, Hengartner H, and Zinkernagel RM (2000) FTY720 immunosuppression impairs effector T cell peripheral homing without affecting induction, expansion, and memory. J Immunol 164:5761-5770.
25. Poirier Y, Antonenkov VD, Glumoff T, and Hiltunen JK (2006) Peroxisomal β-oxidation - a metabolic pathway with multiple functions. Biochim Biophys Acta 1763:1413-1426.
26. Yamanaka M, Anada Y, Igarashi Y, and Kihara A (2008) A splicing isoform of LPP1, LPP1a, exhibits high phosphatase activity toward FTY720 phosphate. Biochem Biophys Res Commun 375:575-579.